Glyceride Esters for the Treatment of Diseases Associated with Reduced Neuronal Metabolism of Glucose
申请人:Hashim Sami A.
公开号:US20090197952A1
公开(公告)日:2009-08-06
Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition.
提供了替代性的酮体来源,以减少或消除帕金森病、肌萎缩侧索硬化症(ALS,也称路易·格里希病)、阿尔茨海默病、亨廷顿病、癫痫和其他以糖代谢受损为特征的疾病或障碍的症状。替代性的酮体来源包括乙酰乙酸单酯、二酯和三酯以及其混合物,和/或3-羟基丁酸单酯、二酯和三酯以及其混合物。这些甘油酯可以口服作为膳食补充剂或营养组成部分。